March 31, 2025
Revolution Medicines to Participate in April 2025 Investor Conferences
February 26, 2025
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
February 24, 2025
Revolution Medicines to Participate in March 2025 Investor Conferences
February 19, 2025
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
January 29, 2025
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
January 6, 2025
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
December 5, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
December 3, 2024
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 2, 2024
Revolution Medicines Announces Commencement of Public Offering of Common Stock
December 2, 2024
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio